These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36697077)

  • 21. Peritoneal Spread of Low-grade Appendiceal Tumours - 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough.
    Rao A; Mui J; Barat S; Matar AA; Alzahrani N; Morris DL
    Anticancer Res; 2021 Nov; 41(11):5569-5575. PubMed ID: 34732427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms.
    Valenzuela CD; Mangieri CW; Garland-Kledzik M; Gawdi R; Russell G; Perry KC; Votanopoulos KI; Levine EA; Shen P
    Ann Surg Oncol; 2022 Jun; 29(6):3422-3431. PubMed ID: 35254575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Milovanov V; Sardi A; Studeman K; Nieroda C; Sittig M; Gushchin V
    Ann Surg Oncol; 2016 Jun; 23(6):1928-33. PubMed ID: 26714951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix.
    Lopez-Ramirez F; Gushchin V; Sittig M; King MC; Baron E; Nikiforchin A; Nieroda C; Sardi A
    Ann Surg Oncol; 2022 Jun; 29(6):3390-3401. PubMed ID: 35133518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of early postoperative intraperitoneal 5-fluorouracil with index cytoreduction improves survival with secondary cytoreductive surgery.
    Sugarbaker PH; Chang D
    J Surg Oncol; 2024 Feb; 129(2):349-357. PubMed ID: 37822274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of Small Bowel Obstruction Post-Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Jedrzejko N; Wong A; MacNeill AJ; Hamilton TD
    J Gastrointest Surg; 2022 Oct; 26(10):2176-2183. PubMed ID: 35852704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC.
    Reghunathan M; Kelly KJ; Valasek MA; Lowy AM; Baumgartner JM
    Ann Surg Oncol; 2018 Mar; 25(3):702-708. PubMed ID: 29282599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Garach NR; Kusamura S; Guaglio M; Bartolini V; Deraco M; Baratti D
    Eur J Surg Oncol; 2021 May; 47(5):1132-1139. PubMed ID: 33280949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma.
    Flood MP; Roberts G; Mitchell C; Ramsay R; Michael M; Heriot AG; Kong JC
    Asia Pac J Clin Oncol; 2024 Feb; 20(1):32-40. PubMed ID: 36880398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical reappraisal of prognostic indicators for 949 mucinous appendiceal neoplasm patients.
    Sugarbaker PH; Chang D
    J Surg Oncol; 2024 Jul; 130(1):140-155. PubMed ID: 38752445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.
    Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA
    Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience.
    Fung X; Li IC; Chandrakumaran K; Cecil T; Dayal S; Tzivanakis A; Moran B; Mohamed F
    Eur J Surg Oncol; 2022 Jul; 48(7):1614-1618. PubMed ID: 35168851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
    Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
    Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early postoperative intraperitoneal chemotherapy is associated with survival benefit for appendiceal adenocarcinoma with peritoneal dissemination.
    Huang Y; Alzahrani NA; Liauw W; Soudy H; Alzahrani AM; Morris DL
    Eur J Surg Oncol; 2017 Dec; 43(12):2292-2298. PubMed ID: 29017824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incomplete cytoreduction with peritoneal metastases from appendiceal mucinous neoplasms.
    Sugarbaker PH; Chang D
    J Surg Oncol; 2022 Dec; 126(8):1462-1470. PubMed ID: 36102369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 38. Oncologic Risk Stratification Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Carcinomatosis.
    Wagner PL; Austin F; Zenati M; Jaech A; Mavanur A; Ramalingam L; Jones HL; Holtzman MP; Ahrendt SA; Zureikat AH; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2016 May; 23(5):1587-93. PubMed ID: 26744106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining "Complete Cytoreduction" After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis.
    Munoz-Zuluaga CA; King MC; Diaz-Sarmiento VS; Studeman K; Sittig M; MacDonald R; Nieroda C; Zambrano-Vera K; Gushchin V; Sardi A
    Ann Surg Oncol; 2020 Dec; 27(13):5026-5036. PubMed ID: 32705513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Waikato, Aotearoa New Zealand: a 12-year experience.
    Qin RX; Lim JH; Ly J; Fischer J; Smith N; Karalus M; Wu L; van Dalen R; Lolohea S
    ANZ J Surg; 2024 Apr; 94(4):621-627. PubMed ID: 37994292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.